DR info

臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 8) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 41

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Acetylcysteine
   Hadassah Medical Organization
      2016   Phase 2/Phase 3   NCT02882477   Israel;
DEPAKINE CHRONO®
   CECS/I-Stem
      -   Phase 2   EUCTR2020-004594-43-FR   France;
Dantrolene sodium
   Washington University School of Medicine
      2017   Phase 1/Phase 2   NCT02829268   United States;
Deferiprone
   Hadassah Medical Organization
      2016   Phase 2/Phase 3   NCT02882477   Israel;
Depakine
   Centre d'Etude des Cellules Souches
      2021   Phase 2   NCT04940572   -
Exenatide
   Hadassah Medical Organization
      2011   -   NCT01302327   -
Sitagliptin and Metformin
   Hadassah Medical Organization
      2016   Phase 2/Phase 3   NCT02882477   Israel;
Sodium Valproate 200Mg E/C Tablet
   University of Birmingham
      2018   Phase 2   NCT03717909   France;Poland;Spain;United Kingdom;
Sodium Valproate Wockhardt 200mg Gastro-Resistant tablets
   University of Birmingham
      2018   Phase 2   EUCTR2017-001215-37-GB   France;Poland;Spain;United Kingdom;
      -   Phase 2   EUCTR2017-001215-37-FR   France;Poland;Spain;United Kingdom;
Sodium valproate 200 mg gastro-resistant tablets
   University of Birmingham
      2020   Phase 2   EUCTR2017-001215-37-PL   France;Poland;United Kingdom;